RhoVac AB
RhoVac AB is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at RhoVac AB.
RhoVac AB is a company.
Key people at RhoVac AB.
Key people at RhoVac AB.
RhoVac AB, now rebranded as CHOSA Oncology AB, is a Sweden-based biotechnology company focused on developing immunotherapeutic drugs, particularly a therapeutic cancer vaccine to prevent or limit metastasis after primary tumor treatment.[1][3][4] Its lead candidate, RV001, is an immuno-oncologic drug that targets RhoC protein-expressing cells with metastatic potential by stimulating T-cells.[1][4] The company serves oncology patients and addresses the critical problem of cancer recurrence and spread post-initial therapy, operating from Lund, Sweden, with a market cap of SEK 87 million as of recent data, though it remains loss-making with negative net profit and equity returns.[1][2]
RhoVac AB specialized in immuno-oncology, leveraging the body's immune system to combat cancer, with a primary focus on RV001.[1][4][5] It underwent a name change to CHOSA Oncology AB, registered by the Swedish Companies Registration Office, maintaining its share structure.[3] The company was founded on January 11, 2023, and is now led by the previous management team from Oncology Venture ApS (rebranded as Allarity Therapeutics), forming a Danish-Swedish biotech entity.[2][6] Key figures include Chairman Gunnar Gardemyr, COO and Director Anders Ljungqvist, and Directors Cristina Glad and Lars Hedbys.[1] This leadership transition and rebranding mark a pivotal evolution from RhoVac's dedicated immuno-oncology focus.[3][5][6]
RhoVac AB (now CHOSA Oncology AB) rides the immuno-oncology trend, where stimulating the immune system—via vaccines and T-cell activation—addresses unmet needs in metastasis prevention, a major cause of cancer mortality.[1][4][5] Timing aligns with advances in precision oncology, as post-primary therapy interventions gain traction amid rising biotech interest in targeted immunotherapies.[1][6] Market forces like increasing cancer incidence and demand for non-chemotherapy options favor its model, while its Swedish-Danish ecosystem leverages Nordic strengths in life sciences R&D.[2][6] It influences the landscape by contributing to the shift toward antigen-specific therapies, potentially expanding the immuno-oncology toolkit beyond CAR-T and checkpoint inhibitors.
CHOSA Oncology AB's path forward hinges on advancing RV001 through clinical stages, with its rebranded structure and seasoned leadership positioning it for partnerships or funding in the competitive immuno-oncology space.[3][6] Trends like AI-driven antigen discovery and combination immunotherapies will shape its trajectory, potentially accelerating metastasis-targeting innovations.[1][4] Its influence may grow if RV001 demonstrates efficacy, evolving from a niche player to a contributor in preventing cancer progression, tying back to its core mission of harnessing immunity against hidden metastatic threats.[1][5]
